J Neurol Surg B Skull Base 2025; 86(S 01): S1-S576
DOI: 10.1055/s-0045-1803307
Presentation Abstracts
Podium Presentations
Oral Presentations

Reduction of Cerebrospinal Fluid Leaks in Idiopathic Intracranial Hypertension with Glucagon-Like Peptide-1 Receptor Agonist Use

Adam S. Vesole
1   Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, United Sates
,
Steven A. Gordon
1   Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, United Sates
,
Jonathan Forbes
2   Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, United Sates
,
Norberto Andaluz
2   Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, United Sates
,
Daniel Q. Sun
1   Department of Otolaryngology—Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, United Sates
› Author Affiliations
 

Introduction: Persistently elevated intracranial pressure (ICP) secondary to idiopathic intracranial hypertension (IIH) is an increasingly recognized risk factor for anterior and lateral skull base cerebrospinal fluid (CSF) leaks. A recent randomized control trial (Mithcell et al. 2023) demonstrated a significant reduction of ICP in IIH with the use glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide), a therapeutic agent for diabetes mellitus and weight loss. No study to date has evaluated the effect of GLP-1 agonists on skull base CSF leaks in IIH.

Methods: A multi-institutional national database (TriNetX) was utilized to identify IIH patients (ICD-10 G93.2) with versus without concurrent GLP-1 agonist use. Propensity score matching was performed to control for potential confounding variables (age, sex, diabetes mellitus, obesity, obstructive sleep apnea; [Table 1]). The rate of spontaneous cranial CSF leak (ICD-10 G96.01) and anterior/lateral skull base CSF leak repair (CPT 62100, 69670, 31290, or 31291) were evaluated between each group over an approximately 1.5-year period.

Zoom

Results: Compared to IIH patients not taking GLP-1 agonists (n = 6,987), IIH patients taking GLP-1 agonists (n = 6,987) were 33% less likely to develop a spontaneous cranial CSF leak (OR: 0.67, 95% CI [0.50–0.89]) and 52% less likely to undergo skull base CSF leak repair (OR: 0.44, 95% CI [0.25–0.93]; [Fig. 1]). BMI in the GLP-1 agonist cohort was reduced by 4.5% over a 3-year period (BMI: 42.1–40.2) compared to a 1.5% decrease in the non-GLP-1 cohort (BMI: 38.5–37.9).

Zoom

Conclusion: We present the first study demonstrating a significantly lower incidence of spontaneous cranial CSF leaks in IIH associated with GLP-1 agonist use. Further, IIH patients using GLP-1 agonists were significantly less likely to undergo anterior and/or lateral skull base CSF leak repair. These promising findings, in conjunction with previous studies exhibiting a sustained reduction in ICP with GLP-1 agonist use, suggest that GLP-1 agonists may be an effective therapeutic agent in CSF leak prophylaxis and resolution in IIH. Future prospective and randomized control studies are needed to better elucidate the relationship of GLP-1 and CSF leaks in IIH.



Publication History

Article published online:
07 February 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany